Selecting Optimal Treatment for Patients With Multiple Sclerosis

Grant number: 1071124 | Funding period: 2014 - 2014

Completed

Abstract

Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal of freedom from disease has become more realistic. We will use the MSBase international multiple sclerosis registry to identify optimal, individually-tailored therapeutic strategies. We will also implement volumetric magnetic resonance imaging in routine practice, thus translating a research tool into an instrument available to patients and their doctors.

Related publications (22)

Scholarly works icon

Association of Sustained Immunotherapy with Disability Outcomes in Patients with Active Secondary Progressive Multiple Sclerosis

T Kalincik, N Lizak, CB Malpas, S Sharmin, EK Havrdova, D Horakova, G Izquierdo, S Eichau, A Lugaresi, P Duquette, M Girard, A Prat, C Larochelle, M Trojano, F Grand'maison, P Grammond, P Sola, D Ferraro, R Hupperts, R Bergamaschi

2020-11-01

Importance: It is unclear whether relapses and disease-modifying therapies are associated with the rate of disability accumulation..

Scholarly works icon

The MSBase registry: Informing clinical practice

T Kalincik, H Butzkueven

2019-12-01

Over the last decade, clinical registries have significantly contributed to the pool of evidence that supports management decision..

Scholarly works icon

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

T Kalincik, V Jokubaitis, T Spelman, D Horakova, E Havrdova, M Trojano, J Lechner-Scott, A Lugaresi, A Prat, M Girard, P Duquette, P Grammond, C Solaro, F Grand’Maison, R Hupperts, J Prevost, P Sola, D Ferraro, M Terzi, E Butler

2018-10-01

Objective: This propensity score–matched analysis from MSBase compared the effectiveness of cladribine with interferon β, fingolim..

Scholarly works icon

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

J Lorscheider, VG Jokubaitis, T Spelman, G Izquierdo, A Lugaresi, E Havrdova, D Horakova, M Trojano, P Duquette, M Girard, A Prat, F Grand'Maison, P Grammond, E Pucci, C Boz, P Sola, D Ferraro, D Spitaleri, J Lechner-Scott, M Terzi

2017-09-05

To investigate the effect of disease-modifying treatment on short-term disability outcomes in secondary progressive multiple scler..

Scholarly works icon

Towards personalized therapy for multiple sclerosis: Prediction of individual treatment response

T Kalincik, A Manouchehrinia, L Sobisek, V Jokubaitis, T Spelman, D Horakova, E Havrdova, M Trojano, G Izquierdo, A Lugaresi, M Girard, A Prat, P Duquette, P Grammond, P Sola, R Hupperts, F Grand'Maison, E Pucci, C Boz, R Alroughani

2017-09-01

Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response var..

Scholarly works icon

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

B Merkel, H Butzkueven, AL Traboulsee, E Havrdova, T Kalincik

2017-06-01

Background Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is associated with imp..

Scholarly works icon

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS

T Spelman, T Kalincik, V Jokubaitis, A Zhang, F Pellegrini, H Wiendl, S Belachew, R Hyde, F Verheul, A Lugaresi, E Havrdová, D Horáková, P Grammond, P Duquette, A Prat, G Iuliano, M Terzi, G Izquierdo, RMM Hupperts, C Boz

2016-04-01

Background: We compared efficacy and treatment persistence in treatment-naive patients with relapsing-remitting multiple sclerosis..

Scholarly works icon

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

M Warrender-Sparkes, T Spelman, G Izquierdo, M Trojano, A Lugaresi, F Grand'Maison, E Havrdova, D Horakova, C Boz, C Oreja-Guevara, R Alroughani, G Iuliano, P Duquette, M Girard, M Terzi, R Hupperts, P Grammond, T Petersen, R Fernandez-Bolaños, M Fiol

2016-04-01

Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatmen..

Scholarly works icon

Defining reliable disability outcomes in multiple sclerosis

T Kalincik, G Cutter, T Spelman, V Jokubaitis, E Havrdova, D Horakova, M Trojano, G Izquierdo, M Girard, P Duquette, A Prat, A Lugaresi, F Grand'Maison, P Grammond, R Hupperts, C Oreja-Guevara, C Boz, E Pucci, R Bergamaschi, J Lechner-Scott

2015-11-01

Prevention of irreversible disability is currently the most important goal of disease modifying therapy for multiple sclerosis. Th..

Scholarly works icon

10-year progression predictors after first treatment initiation in a relapsing-remitting MS cohort

VG Jokubaitis, T Spelman, T Kalincik, D Travaglini, D Paolicelli, P Duquette, M Girard, A Prat, E Havrdova, D Horakova, G Izquierdo, P Grammond, E Pucci, F Grand'Maison, R Bergamaschi, F Granella, V Van Pesch, R Hupperts, G Iuliano, D Spitaleri

2015-09-01

Scholarly works icon

Comparative efficacy of first-line natalizumab versus IFNb or glatiramer acetate in relapsing MS

T Spelman, T Kalincik, V Jokubaitis, A Zhang, F Pellegrini, H Wiendl, S Belachew, R Hyde, F Verheul, A Lugaresi, E Havrdova, D Horakova, P Grammond, P Duquette, A Prat, G Iuliano, M Terzi, G Izquierdo, R Hupperts, C Boz

2015-09-01

Scholarly works icon

Defining secondary progressive multiple sclerosis

J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, D Horakova, M Trojano, G Izquierdo, M Girard, P Duquette, A Prat, A Lugaresi, F Grand'Maison, P Grammond, R Hupperts, R Alroughani, P Sola, C Boz, M Terzi, E Pucci

2015-09-01

Scholarly works icon

Effect of relapse phenotype on the accumulation of disability in relapsing-remitting multiple sclerosis

T Stewart, V Jokubaitis, T Spelman, E Havrdova, D Horakova, M Trojano, G Izquierdo, M Girard, P Duquette, A Prat, A Lugaresi, P Grammond, F Grand'Maison, P Sola, R Hupperts, T Petersen, E Pucci, R Bergamaschi, C Boz, C Oreja-Guevara

2015-09-01

Scholarly works icon

Immunomodulatory therapy slows accumulation of disability in moderately advanced multiple sclerosis

N Lizak, A Lugaresi, R Alroughani, J Lechner-Scott, M Slee, E Havrdova, D Horakova, M Trojano, G Izquierdo, P Duquette, M Girard, A Prat, P Grammond, R Hupperts, P Sola, F Grand'Maison, R Bergamaschi, E Pucci, C Oreja-Guevara, JA Cabrera-Gomez

2015-09-01

Scholarly works icon

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

T Kalincik, V Jokubaitis, G Izquierdo, P Duquette, M Girard, P Grammond, A Lugaresi, C Oreja-Guevara, R Bergamaschi, R Hupperts, F Grandmaison, E Pucci, V Van Pesch, C Boz, G Iuliano, R Fernandez-Bolanos, S Flechter, D Spitaleri, E Cristiano, F Verheul

2015-08-25

Background: The results of head-to-head comparisons of injectable immunomodulators (interferon β, glatiramer acetate) have been in..

Scholarly works icon

Multiple sclerosis relapses: Epidemiology, outcomes and management. A systematic review

T Kalincik

2015-08-20

Relapses (episodic exacerbations of neurological signs or symptoms) are a defining feature of relapsing-remitting multiple scleros..

Scholarly works icon

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

A He, T Spelman, V Jokubaitis, E Havrdova, D Horakova, M Trojano, A Lugaresi, G Izquierdo, P Grammond, P Duquette, M Girard, E Pucci, G Iuliano, R Alroughani, C Oreja-Guevara, R Fernandez-Bolaños, F Grand'Maison, P Sola, D Spitaleri, F Granella

2015-04-01

IMPORTANCE: After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicia..

Scholarly works icon

Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis

M Tyblova, T Kalincik, V Zikan, E Havrdova

2015-04-01

Background and purpose: The prevalence of osteopenia and osteoporosis is higher amongst patients with multiple sclerosis in compar..

Scholarly works icon

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, G Izquierdo, C Rozsa, P Grammond, R Alroughani, P Duquette, M Girard, E Pucci, J Lechner-Scott, M Slee, R Fernandez-Bolanos, F Grand'Maison, R Hupperts, F Verheul, S Hodgkinson

2015-03-01

Objective: In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians..

Scholarly works icon

Comparative efficacy of switching to natalizumab in active multiple sclerosis

T Spelman, T Kalincik, A Zhang, F Pellegrini, H Wiendl, L Kappos, L Tsvetkova, S Belachew, R Hyde, F Verheul, F Grand-Maison, G Izquierdo, P Grammond, P Duquette, A Lugaresi, J Lechner-Scott, C Oreja-Guevara, R Hupperts, T Petersen, M Barnett

2015-01-01

Objective: To compare treatment efficacy and persistence in patients who switched to natalizumab versus those who switched between..

Scholarly works icon

Risk of relapse phenotype recurrence in multiple sclerosis

T Kalincik, K Buzzard, V Jokubaitis, M Trojano, P Duquette, G Izquierdo, M Girard, A Lugaresi, P Grammond, F Grand'Maison, C Oreja-Guevara, C Boz, R Hupperts, T Petersen, G Giuliani, G Iuliano, J Lechner-Scott, M Barnett, R Bergamaschi, V Van Pesch

2014-10-19

Objectives: The aim was to analyse risk of relapse phenotype recurrence in multiple sclerosis and to characterise the effect of de..

Scholarly works icon

Comparative efficacy of switch to natalizumab or fingolimod in active relapsing-remitting multiple sclerosis

T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, G Izquierdo, C Rozsa, P Grammond, R Alroughani, P Duquette, M Girard, E Pucci, J Lechner-Scott, M Slee, R Fernandez-Bolanos, F Grand'Maison, R Hupperts, F Verheul, S Hodgkinson

2014-09-01

University of Melbourne Researchers